Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161629 | 0.91 | NPC1 (0.44) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL1285120 | 0.82 | OPRM1 (0.68) | OPRM1OPRD1 | |
| SCHEMBL17316802 | 0.79 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL432561 | 0.78 | OPRM1 (0.59) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL12470590 | 0.76 | OPRM1 (0.41) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL12471130 | 0.76 | OPRM1 (0.33) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL23588025 | 0.74 | ESR1 (0.46) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL1020434 | 0.74 | OPRM1 (0.70) | OPRM1 | |
| SCHEMBL5201558 | 0.74 | OPRM1 (0.42) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL16025351 | 0.74 | OPRM1 (0.46) | OPRM1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265102-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-24 | — | — | US | claimed |
| EP-4208447-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Syngenta Crop Protection AG (CH) | 2023-07-12 | — | — | EP | claimed |
| CN-116234811-A | Pesticidally active heterocyclic derivatives with sulfur containing substituents | 先正达农作物保护股份公司 | 2023-06-06 | — | — | CN | claimed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | claimed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | claimed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | claimed |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | US | claimed |
| WO-2013024130-A1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | claimed |
| EP-2536733-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2012-12-26 | — | — | EP | claimed |
| WO-2012110599-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | WO | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | claimed |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | claimed |
| WO-2011101424-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | OPRM1 715/4885CA12 4321/4885CA1 1079/4885 |
| US-20230265102-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | ACHE, SQOR, DDT | OPRM1 3236/4885CA12 2825/4885CA1 583/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | OPRM1 609/4885CA12 3768/4885CA1 589/4885 |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | CETP, MTTP, NPC1L1 | OPRM1 3183/4885CA12 4573/4885CA1 4636/4885 |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | OPRM1 2879/4885CA12 4206/4885CA1 4074/4885 |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | CETP, MTTP, CES1 | OPRM1 2879/4885CA12 4206/4885CA1 4074/4885 |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | OPRM1 2879/4885CA12 4206/4885CA1 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.